The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists

Authors

  • Lionel Noronha, MD

DOI:

https://doi.org/10.58931/cpct.2023.1S0717

Abstract

The wave of diabetes continues to increase in Canada and around the world. According to national data, 3.4 million Canadians were living with diabetes (type 1 and type 2 combined) in 2017–2018, compared to 1.3 million in 2000–2001. It is well-accepted that diabetes is a major cause of death and is the leading cause of renal failure, lower limb amputations and blindness in adults.

Author Biography

Lionel Noronha, MD

Dr. Lionel Noronha graduated from the University of Toronto medical school in 1990 and completed his family medicine residency there in 1992. He was awarded the Gaynor Dawn Memorial scholarship in family medicine. He is the medical director of the Stirling Manor and the lead physician for the Belleville family health organization. He has been a clinical investigator in numerous studies and also has published in peer-reviewed journals. He has a passion for CME and has given over 250 talks to other physicians as well as nurses, pharmacists and diabetic educators.

References

Public Health Agency of Canada. Canadian Chronic Disease Surveillance System (CCDSS) [Internet]. Public Health Agency of Canada. 2017 [accessed 2019 Sept 2013].

Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7;358(6):580-591. DOI: https://doi.org/10.1056/NEJMoa0706245

DCCT Research Group. Diabetes control and complications trial (DCCT): update. Diabetes Care.1990:427-433. DOI: https://doi.org/10.2337/diacare.13.4.427

King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmcol. 1999:48(5):643. DOI: https://doi.org/10.1046/j.1365-2125.1999.00092.x

Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009:360;2:129-139. DOI: https://doi.org/10.1056/NEJMoa0808431

ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008:358(24):2560-2572. DOI: https://doi.org/10.1056/NEJMoa0802987

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005:353(25): 2643-2653. DOI: https://doi.org/10.1056/NEJMoa052187

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007:356(24):2457-2471. DOI: https://doi.org/10.1056/NEJMoa072761

Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015:373(3):232-242. DOI: https://doi.org/10.1056/NEJMoa1501352

Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013:369(14):1317-1326. DOI: https://doi.org/10.1056/NEJMoa1307684

Rosenstock J, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019:321(1):69-79. DOI: https://doi.org/10.1001/jama.2018.18269

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015:373(22):2117-2128. DOI: https://doi.org/10.1056/NEJMoa1504720

Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016:375(4):311-322. DOI: https://doi.org/10.1056/NEJMoa1603827

Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017:377(7):644-657. DOI: https://doi.org/10.1056/NEJMoa1611925

Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019:380(4):347-357. DOI: https://doi.org/10.1056/NEJMoa1812389

Lipscombe L, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes. 2020:44(7):575-591. DOI: https://doi.org/10.1016/j.jcjd.2020.08.001

Marso SP. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016:375:1834-1844. DOI: https://doi.org/10.1056/NEJMoa1607141

Husain, M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019:381(9): 841-851. DOI: https://doi.org/10.1056/NEJMoa1901118

Aroda VR. Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;4 (9):1724-1732. DOI: https://doi.org/10.2337/dc19-0749

Laiteerapong N. The legacy effect in type 2 diabetes: impact of early glycemic control on future (The Diabetes and Aging Study). Diabetes Care. 2019;42(3):416-426. DOI: https://doi.org/10.2337/dc17-1144

Lachlin JM. The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes. Diabetes Care. 2021:44(10):2225‑2230. DOI: https://doi.org/10.2337/dc21-1331

Downloads

Published

2023-07-12

How to Cite

1.
Noronha L. The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists. Can Prim Care Today [Internet]. 2023 Jul. 12 [cited 2025 Jan. 22];1(S07):2–6. Available from: https://canadianprimarycaretoday.com/article/view/1-s07-noronha

Issue

Special Supplement, July 2023

Section

Articles

License

Copyright (c) 2023 Canadian Primary Care Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.